Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".

Published

Journal Article (Letter)

Full Text

Duke Authors

Blazing, Michael August

Cited Authors

Bohula, EA; Giugliano, RP; Cannon, CP; Zhou, J; Murphy, SA; White, J; Tershakovec, AM; Blazing, MA; Braunwald, E

Published Date

March 29, 2016

Published In

Circulation

Volume / Issue

133 / 13

Start / End Page

e463 -

PubMed ID

27022050

Pubmed Central ID

27022050

Electronic International Standard Serial Number (EISSN)

1524-4539

Digital Object Identifier (DOI)

10.1161/CIRCULATIONAHA.116.020947

Language

eng

Conference Location

United States